As the CRISPR-Cas9 war still goes on, CRISPR Therapeutics closed a Series A and B financing round with €79.5M. The oversubscribed financing rounds were led by strategic investors, GlaxoSmithKline‘s SR One and Celgene Corporation, respectively and also included other actors already known by the company, such as Versant Ventures, along with new ones namely New Enterprise Associates (NEA) and Abingworth.
Despite the CRISPR-Cas9 battle being very much alive and kicking about, this embodies no impediment for startups focused on this disrupting technology to continue receiving venture money. This time, it’s CRIPR Therapeutics who overtook the race, raising €79.5M (around €31M in the Series A and about €25.9M in the Series B).
The company trusts that this venture cash will help them to rapidly translate the novel gene- editing technology into life-changing medicines for patients. The capital will also be invested in CRISPR’s strategic new office in Massachusetts. The center of operations, inaugurated at the beginning of April, will be the company’s cornerstone, as Fierce Biotech reported.
In addition, Simeon George, from SR One, Ali Behbahani, from NEA, and Kurt von Emster, from Abingworth, will join CRISPR Therapeutics’ Board of Directors.
Simeon George, commented: “CRISPR-Cas9 is a fundamental breakthrough that enables us to address the root cause of multiple diseases through gene-editing. We are excited to be part of the very talented team from academia and industry at CRISPR Therapeutics, as they embark on a very compelling mission to transform patient care by bringing CRISPR-Cas9 into the clinic.“
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.